The recent publication in the New England Journal of Medicine highlighting an increased incidence of hematologic cancers in patients treated with Bluebird Bio’s Skysona product has raised concerns ...
Seven young boys given Bluebird's Skysona later developed blood cancers, findings that could shape how doctors balance the gene therapy’s risks against its benefit.